

# Viktor Umansky

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7304637/viktor-umansky-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99  
papers

7,242  
citations

44  
h-index

84  
g-index

108  
ext. papers

9,417  
ext. citations

7.9  
avg, IF

6  
L-index

#	Paper	IF	Citations
99	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. <b>2022</b> , 10,		1
98	Involvement of platelet-derived VWF in metastatic growth of melanoma in the brain.. <i>Neuro-Oncology Advances</i> , <b>2021</b> , 3, vdab175	0.9	0
97	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , <b>2021</b> , 592, 450-456	50.4	164
96	FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 657-674	7.5	1
95	Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	8
94	Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1628-1638	7.5	2
93	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. <i>Cellular Immunology</i> , <b>2021</b> , 359, 104254	4.4	26
92	Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. <i>Cellular Immunology</i> , <b>2021</b> , 360, 104274	4.4	3
91	Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
90	Depletion and Maturation of Myeloid-Derived Suppressor Cells in Murine Cancer Models. <i>Methods in Molecular Biology</i> , <b>2021</b> , 2236, 67-75	1.4	2
89	Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors. <i>Oncolimmunology</i> , <b>2020</b> , 9, 1727116	7.2	21
88	T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1023-1036	8.7	13
87	Dormant tumor cells interact with memory CD8 T cells in RET transgenic mouse melanoma model. <i>Cancer Letters</i> , <b>2020</b> , 474, 74-81	9.9	8
86	Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. <i>Oncolimmunology</i> , <b>2020</b> , 9, 1744946	7.2	13
85	Perspective [Escape from destruction: how cancer-derived EVs are protected from phagocytosis. <i>Trillium Extracellular Vesicles</i> , <b>2020</b> , 2, 60-64	0.2	0
84	Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma. <i>Molecular Therapy - Oncolytics</i> , <b>2020</b> , 18, 83-99	6.4	7
83	IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma <b>2020</b> , 8,		25

82	Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	7
81	Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation <b>2020</b> , 8,		46
80	SOX2 in development and cancer biology. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 67, 74-82	12.7	71
79	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	20
78	Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 687-697	7.4	103
77	Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3462-3477	7.5	28
76	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. <i>Cancers</i> , <b>2019</b> , 11,	6.6	9
75	A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 909-921	7.5	1
74	Interactions among myeloid regulatory cells in cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 645-660	7.4	28
73	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. <i>Cancer Research</i> , <b>2019</b> , 79, 4715-4728	10.1	51
72	ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 760	9.8	10
71	Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 1998-2012	12.5	8
70	Fighting infant infections with myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4080-4082	15.9	3
69	Complex Formation with Monomeric $\beta$ -Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun $\beta$ Nuclear Translocation and Activity. <i>Cancers</i> , <b>2019</b> , 11,	6.6	3
68	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 16-25	8.7	235
67	Opposing roles of eosinophils in cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2019</b> , 68, 823-833	7.4	57
66	Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. <i>OncImmunology</i> , <b>2018</b> , 7, e1442167	7.2	44
65	Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models. <i>OncImmunology</i> , <b>2018</b> , 7, e1445457	7.2	9

64	Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 198, 777-787	10.2	79
63	CCR5 Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. <i>Cancer Research</i> , <b>2018</b> , 78, 157-167	10.1	82
62	Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 398	8.4	274
61	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 1310	8.4	260
60	Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2962-2972	7.5	17
59	SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 3131-3142	7.5	34
58	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 5505-5516	15.9	120
57	The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment. <i>Wspolczesna Onkologia</i> , <b>2018</b> , 22, 7-13	1	17
56	Targeting SOX2 in anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , <b>2018</b> , 22, 983-991	6.4	36
55	Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. <i>Oncotmunology</i> , <b>2017</b> , 6, e1258503	7.2	10
54	CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2017</b> , 66, 1015-1023	7.4	56
53	Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. <i>Stem Cell Reports</i> , <b>2017</b> , 8, 1379-1391	8	25
52	Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe). <i>Oncotmunology</i> , <b>2017</b> , 6, e1326440	7.2	51
51	CCR5 Directs the Mobilization of CD11bGr1Ly6C Polymorphonuclear Myeloid Cells from the Bone Marrow to the Blood to Support Tumor Development. <i>Cell Reports</i> , <b>2017</b> , 21, 2212-2222	10.6	52
50	Myeloid-derived suppressor cells and tumor escape from immune surveillance. <i>Seminars in Immunopathology</i> , <b>2017</b> , 39, 295-305	12	49
49	Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. <i>Nature Communications</i> , <b>2016</b> , 7, 12150	17.4	1388
48	Incipient Melanoma Brain Metastases Instigate Astrogliosis and Neuroinflammation. <i>Cancer Research</i> , <b>2016</b> , 76, 4359-71	10.1	54
47	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. <i>Oncotmunology</i> , <b>2016</b> , 5, e1160183	7.2	3

46	Predictive immune markers in advanced melanoma patients treated with ipilimumab. <i>Oncolmunology</i> , <b>2016</b> , 5, e1158901	7.2	16
45	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 921-37	15.9	48
44	Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. <i>Oncotarget</i> , <b>2016</b> , 7, 68527-68545	3.3	24
43	The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. <i>Vaccines</i> , <b>2016</b> , 4,	5.3	187
42	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. <i>Stem Cells</i> , <b>2016</b> , 34, 832-46	5.8	18
41	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF $\beta$ Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. <i>Journal of Immunotherapy</i> , <b>2016</b> , 39, 343-354	5	17
40	Ret mouse very large tumors (VLTs) display altered ratios of infiltrating memory to naive T cells: Roles in tumor expansion. <i>Pathophysiology</i> , <b>2016</b> , 23, 211-20	1.8	1
39	Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection. <i>Oncolmunology</i> , <b>2016</b> , 5, e1204506	7.2	36
38	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. <i>Oncolmunology</i> , <b>2015</b> , 4, e1008371	7.2	182
37	Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. <i>Oncolmunology</i> , <b>2015</b> , 4, e998519	7.2	67
36	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 5453-9	12.9	237
35	Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 2352-60	7.5	112
34	von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. <i>Blood</i> , <b>2015</b> , 125, 3153-63	2.2	86
33	Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2607-17	7.5	22
32	Extracellular adenosine metabolism in immune cells in melanoma. <i>Cancer Immunology, Immunotherapy</i> , <b>2014</b> , 63, 1073-80	7.4	42
31	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. <i>Seminars in Cancer Biology</i> , <b>2014</b> , 23, 51-7	12.7	58
30	CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. <i>Molecular Therapy</i> , <b>2014</b> , 22, 1949-59	11.7	212
29	Myeloid-derived suppressor cells in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-7	1.2	33

28	Myeloide Suppressorzellen (MDSC) beim malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , <b>2014</b> , 12, 1021-1027	1.2	13
27	Harnessing high density lipoproteins to block transforming growth factor beta and to inhibit the growth of liver tumor metastases. <i>PLoS ONE</i> , <b>2014</b> , 9, e96799	3.7	10
26	Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals. <i>Oncotarget</i> , <b>2014</b> , 5, 4516-28	3.3	20
25	Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 36691-702	5.4	167
24	Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 1610-9	4.3	79
23	Tumor microenvironment and myeloid-derived suppressor cells. <i>Cancer Microenvironment</i> , <b>2013</b> , 6, 169-77	4.1	90
22	Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 98-107	7.5	116
21	Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. <i>Pigment Cell and Melanoma Research</i> , <b>2013</b> , 26, 457-63	4.5	9
20	Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. <i>Journal of Immunology</i> , <b>2013</b> , 190, 2464-71	5.3	156
19	ChemImmunoModulation: Focus on Myeloid Regulatory Cells <b>2013</b> , 603-619		
18	Melanoma-induced immunosuppression and its neutralization. <i>Seminars in Cancer Biology</i> , <b>2012</b> , 22, 319-26	2.7	89
17	Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 275-282	7.4	50
16	Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. <i>Journal of Immunotoxicology</i> , <b>2012</b> , 9, 292-300	3.1	98
15	Characterization and longitudinal monitoring of melanoma growth in ret-transgenic mice using a single-sequence MRI protocol. <i>Experimental Dermatology</i> , <b>2012</b> , 21, 837-41	4	
14	Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. <i>Journal of Immunology</i> , <b>2012</b> , 189, 5602-11	5.3	261
13	T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma. <i>Cancers</i> , <b>2012</b> , 4, 490-503	6.6	14
12	New strategies for melanoma immunotherapy: How to overcome immunosuppression in the tumor microenvironment. <i>Oncolimmunology</i> , <b>2012</b> , 1, 765-767	7.2	5
11	Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1239-46	4.3	96

10	Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. <i>Journal of Immunotoxicology</i> , <b>2012</b> , 9, 275-81	3.1	45
9	Comment on "Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b(+)Gr1(+) cells". <i>Journal of Immunology</i> , <b>2012</b> , 188, 2929-30; author reply 1930	5.3	11
8	Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 17111-6	11.5	255
7	Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4382-90	12.9	63
6	Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. <i>Journal of Immunology</i> , <b>2009</b> , 183, 6330-7	5.3	50
5	Effect of artesunate on immune cells in ret-transgenic mouse melanoma model. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 910-7	2.4	23
4	Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. <i>Cancer Research</i> , <b>2008</b> , 68, 9451-8	10.1	58
3	Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. <i>Cancer Research</i> , <b>2006</b> , 66, 5997-6001	10.1	29
2	Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 67-76	15.9	94
1	Bone marrow as a priming site for T-cell responses to blood-borne antigen. <i>Nature Medicine</i> , <b>2003</b> , 9, 1151-7	50.5	262